EMEA-002074-PIP01-16

Key facts

Invented name
Cyramza
Active substance
Ramucirumab
Therapeutic area
Oncology
Decision number
P/0282/2017
PIP number
EMEA-002074-PIP01-16
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma
  • Treatment of intestinal malignant neoplasms
  • Treatment of liver cancer
  • Treatment of lung malignant neoplasms
  • Treatment of urinary tract malignant neoplasm
Route(s) of administration
Intravenous use
Contact for public enquiries
Eli Lilly and Company Limited

Tel. +44 1276483000
E-mail: eu_paediatric@lilly.com
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating